Press News

Press News

2013.05.02 Notice regarding the Establishment of a Subsidiary New Entry into ‘Imaging CRO’ Clinical Trial Support Business Using the Latest Imaging Technology and Concentrating in New Anti-cancer Treatments

tella, Inc. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Yuichiro Yazaki; hereinafter “the Company”) established TITAN Inc. (Head office: Chiyoda-ku, Tokyo; President: Toru Mafune; hereinafter “Titan”) today for the purpose of newly participating in ‘Imaging CRO (Contract Research Organization’*1) clinical trial support operations using the latest imaging testing technology and concentrating in new drugs for cancer. At present, global clinical trials are steadily becoming more dominant as the normal method for testing of newly developed drugs conducted in Japan. Moreover, given that there are few effective treatments for cancer and central nervous system patients, the ability to evaluate the efficacy and safety of drugs more accurately and rapidly is very much in demand, and so there has been an increase in activity internationally in projects seeking to evaluate such drugs using biomarkers*2 that can quantify the changes in the characteristics of the disease in response to the drugs. Amongst these, attention is centering on CT*3, PET*4, and MRI*5 as outcome measures for biomarkers. Evaluation of tumor shrinkage efficacy, etc. employing CT on the basis of RECIST Guidelines*7 has become the norm in evaluating the efficacy of Phase II clinical trials*6 on reducing the size of solid carcinomas. This can be done rapidly using imaging equipment. However, the development of imaging equipment, imaging protocols etc. for obtaining images, requires knowledge in a wide range of areas, including medicine, pharmacology and engineering.

Titan, in association with Lisit, Co., Ltd. (Head office: Shibuya-ku, Tokyo, President (CEO/CTO): Shuji Yamamoto; hereinafter “Lisit”) and MITT Co., Ltd. (Head Office: Sapporo City, Hokkaido, Representative Director: Tadashi Tsuchimoto; hereinafter “MITT”), is using the latest imaging testing technology and know-how to provide clinical trials support services for cancer and central nervous system related patients. Titan is, by making use of systems owned by Lisit and MITT, exploiting specialized imaging testing tools specifically used for clinical trials in accordance with international standards, and conducting online conferences with imaging evaluation committees to support both clinical trials in Asia and global clinical trials for which demand is expected to grow in the future. The Company is committed to contributing to the development of cancer treatments by entering the imaging CRO business specializing in cancer. This matter will have only a negligible effect on results of operations in fiscal 2013.

TopPage